000154382 001__ 154382
000154382 005__ 20240320115506.0
000154382 0247_ $$2doi$$a10.1002/mds.28192
000154382 0247_ $$2pmid$$apmid:33179332
000154382 0247_ $$2ISSN$$a0885-3185
000154382 0247_ $$2ISSN$$a1531-8257
000154382 0247_ $$2altmetric$$aaltmetric:88324526
000154382 037__ $$aDZNE-2021-00235
000154382 041__ $$aEnglish
000154382 082__ $$a610
000154382 1001_ $$0P:(DE-HGF)0$$aMarkaki, Ioanna$$b0$$eCorresponding author
000154382 245__ $$aCerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
000154382 260__ $$aNew York, NY$$bWiley$$c2020
000154382 3367_ $$2DRIVER$$aarticle
000154382 3367_ $$2DataCite$$aOutput Types/Journal article
000154382 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1617289421_15300
000154382 3367_ $$2BibTeX$$aARTICLE
000154382 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154382 3367_ $$00$$2EndNote$$aJournal Article
000154382 500__ $$aISSN 1531-8257 not unique: **3 hits**.
000154382 520__ $$aCognitive impairment is common in patients with PD. Core markers of Alzheimer's dementia have been related also to PD dementia, but no disease-specific signature to predict PD dementia exists to date.The aim of this study was to investigate CSF markers associated with cognition in early PD.A high-throughput suspension bead array examined 216 proteins in CSF of 74 PD patients in the AETIONOMY project. Cognitive function was assessed with Repeatable Battery for the Assessment of the Neuropsychological Status, Montreal Cognitive Assessment, and Mini-Mental State Examination.Of 69 patients with complete data, 34 had high (≥90) and 35 had low Repeatable Battery for the Assessment of the Neuropsychological Status total score (<90). Of 14 proteins in CSF that differed in levels between groups, increased kininogen-1, validated with several antibodies, was independently associated with lower Repeatable Battery for the Assessment of the Neuropsychological Status and Montreal Cognitive Assessment scores after adjustment for confounders.Kininogen-1 levels in CSF may serve as a marker of cognitive impairment in PD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000154382 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000154382 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000154382 650_7 $$2Other$$aParkinson's disease
000154382 650_7 $$2Other$$acognition
000154382 650_7 $$2Other$$akininogen-1
000154382 650_7 $$2Other$$aneurodegeneration
000154382 650_2 $$2MeSH$$aCognition Disorders: diagnosis
000154382 650_2 $$2MeSH$$aCognition Disorders: etiology
000154382 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000154382 650_2 $$2MeSH$$aHumans
000154382 650_2 $$2MeSH$$aKininogens
000154382 650_2 $$2MeSH$$aMental Status and Dementia Tests
000154382 650_2 $$2MeSH$$aNeuropsychological Tests
000154382 650_2 $$2MeSH$$aParkinson Disease: complications
000154382 7001_ $$aBergström, Sofia$$b1
000154382 7001_ $$aTsitsi, Panagiota$$b2
000154382 7001_ $$aRemnestål, Julia$$b3
000154382 7001_ $$aMånberg, Anna$$b4
000154382 7001_ $$aHertz, Ellen$$b5
000154382 7001_ $$aPaslawski, Wojciech$$b6
000154382 7001_ $$aSorjonen, Kimmo$$b7
000154382 7001_ $$aUhlén, Mathias$$b8
000154382 7001_ $$aMangone, Graziella$$b9
000154382 7001_ $$aCarvalho, Stephanie$$b10
000154382 7001_ $$aRascol, Olivier$$b11
000154382 7001_ $$0P:(DE-HGF)0$$aMeissner, Wassilios G$$b12
000154382 7001_ $$aMagnin, Eloi$$b13
000154382 7001_ $$0P:(DE-2719)2000056$$aWüllner, Ullrich$$b14$$udzne
000154382 7001_ $$aCorvol, Jean-Christophe$$b15
000154382 7001_ $$aNilsson, Peter$$b16
000154382 7001_ $$aSvenningsson, Per$$b17
000154382 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.28192$$gVol. 35, no. 11, p. 2101 - 2106$$n11$$p2101 - 2106$$tMovement disorders$$v35$$x1531-8257$$y2020
000154382 8564_ $$uhttps://pub.dzne.de/record/154382/files/mds.28192.pdf$$yOpenAccess
000154382 8564_ $$uhttps://pub.dzne.de/record/154382/files/mds.28192.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000154382 909CO $$ooai:pub.dzne.de:154382$$pdnbdelivery$$popenaire$$pdriver$$pVDB$$popen_access
000154382 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000056$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000154382 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000154382 9132_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000154382 9141_ $$y2020
000154382 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000154382 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000154382 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000154382 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000154382 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000154382 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2021$$d2022-11-11
000154382 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000154382 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000154382 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000154382 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000154382 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000154382 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2021$$d2022-11-11
000154382 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000154382 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000154382 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000154382 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000154382 9201_ $$0I:(DE-2719)1011302$$kAG Wüllner ; AG Wüllner 2$$lBiomarkers for Parkinson's disease$$x0
000154382 980__ $$ajournal
000154382 980__ $$aVDB
000154382 980__ $$aUNRESTRICTED
000154382 980__ $$aI:(DE-2719)1011302
000154382 9801_ $$aFullTexts